The familial risk of endometriosis.

Acta Obstet Gynecol Scand

Department of Obstetrics and Gynecology, National Hospital, University of Oslo, Norway.

Published: October 1993

Objective: To study the occurrence of endometriosis or adenomyosis in mothers and sisters of patients with endometriosis.

Methods: A total of 563 patients with endometriosis were interviewed about endometriosis or adenomyosis in their mothers or sisters. Five hundred and twenty-eight patients (94%) gave information about their relatives. Six patients were adopted and had no knowledge about their relatives. Among 522 patients were seven pairs of sisters, of which only one was included, giving a total of 515 cases. The control group consisted of 149 women without endometriosis documented at a recently diagnostic laparoscopy performed in connection with sterilization. The controls were likewise interviewed about their relatives, and none refused to give information. If a gynecological operation in a relative was reported, medical records were obtained (68%) or a description of the medical history was given by the proband.

Results: Endometriosis or adenomyosis was disclosed in 3.9% of mothers of cases and in 0.7% of mothers of controls, in 4.8% of sisters of cases and in 0.6% of sisters of controls. The relative risk of endometriosis in a first-degree relative (expressed as odds ratio), was 7.2 (95% confidence interval 2.1, 24.3). Severe manifestations of endometriosis were found more often among patients with a positive family history than among those without (26% versus 12%, p < 0.01).

Conclusion: The study demonstrates a seven fold increased risk of endometriosis in mothers and sisters of patients with endometriosis. It is assumed that daughters of patients with endometriosis have a similar risk of developing endometriosis.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00016349309058164DOI Listing

Publication Analysis

Top Keywords

endometriosis
12
risk endometriosis
12
endometriosis adenomyosis
12
mothers sisters
12
patients endometriosis
12
adenomyosis mothers
8
patients
8
sisters patients
8
sisters
6
mothers
5

Similar Publications

Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Application of artificial intelligence to ultrasound imaging for benign gynecological disorders: systematic review.

Ultrasound Obstet Gynecol

January 2025

Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.

Objective: Although artificial intelligence (AI) is increasingly being applied to ultrasound imaging in gynecology, efforts to synthesize the available evidence have been inadequate. The aim of this systematic review was to summarize and evaluate the literature on the role of AI applied to ultrasound imaging in benign gynecological disorders.

Methods: Web of Science, PubMed and Scopus databases were searched from inception until August 2024.

View Article and Find Full Text PDF

Objectives: To estimate the prevalence of heavy menstrual bleeding among Australian women from young adulthood to midlife (22-48 years) and investigate the characteristics of women who experience this condition; to investigate the relationship of heavy menstrual bleeding and health-related quality of life.

Study Design: Longitudinal cohort survey study (Australian Longitudinal Study on Women's Health, ALSWH).

Setting, Participants: Australia; baseline cohort of 14 247 women born during 1973-1978, recruited in 1996; eight post-baseline surveys undertaken at 3-year intervals, 2000-2021.

View Article and Find Full Text PDF

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h.

View Article and Find Full Text PDF

Influence of Hormonal Contraceptive Usage on Risk of Endometriosis.

BJOG

January 2025

Department of Obstetrics and Gynecology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!